Prescription medicine
Bimekizumab Brand names: Bimzelx
Bimekizumab (Bimzelx) is a prescription medicine. No generic is listed; pharmacies paid $8,073.83 per mL (Bimzelx 160 mg/mL autoinjector) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the bimekizumab FDA label on DailyMed (effective June 16, 2025); every bimekizumab label on DailyMed.
Highlights of the record
FDA label of June 16, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageBIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy.
Forms and strengths
- 160 mg/ml
- 320 mg/2ml
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $8,073.83 per mL Bimzelx 160 mg/mL autoinjector
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 21,176 through July 30, 2026
What is bimekizumab used for?
From the label: indications and usageBIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA). ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS). […]
Conditions named in the indications of bimekizumab's FDA labels, with every medicine labeled for each:
From other bimekizumab labelsPsoriasis: Plaque Psoriasis BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Source: FDA drug label (Bimzelx), UCB, Inc., effective June 16, 2025 (SPL set 26b88358-871f-4c80-9d80-b2fb16477f81), via openFDA; the full label on DailyMed
What does the patient leaflet for bimekizumab say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about BIMZELX?BIMZELX is a medicine that affects your immune system. BIMZELX may increase your risk of having serious side effects, including: Suicidal thoughts and behavior. New or worsening suicidal thoughts and behavior have happened in some people treated with BIMZELX. Get medical help right away or call the National Suicide and Crisis Lifeline at 988 if you, your caregiver or your family member notice in you any of the following symptoms: new or worsening depression or anxiety thoughts of suicide, dying, or hurting yourself changes in behavior or mood acting on dangerous impulses attempt to commit suicide Infections. BIMZELX is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections, including serious infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with BIMZELX. If your healthcare provider feels you are at risk for TB, you may be treated with medicine for TB before you begin treatment with BIMZELX and during your treatment with BIMZELX. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with BIMZELX. Do not take BIMZELX if you have an active TB infection. […]
From the patient leaflet: How should I store BIMZELX?Store BIMZELX in the refrigerator between 36°F to 46°F (2°C to 8°C). BIMZELX may be stored at room temperature up to 77°F (25°C) for up to 30 days in the original carton. Do not place BIMZELX prefilled syringes or autoinjectors back in the refrigerator after they have been stored at room temperature. Write the date removed from the refrigerator in the space provided on the carton and throw away BIMZELX if it has been kept at room temperature and not been used within 30 days. Keep BIMZELX in the original carton until ready for use to protect from light. Do not freeze BIMZELX. Do not shake BIMZELX. Do not use BIMZELX past the expiration date printed on the carton. Keep BIMZELX and all medicines out of the reach of children.
Source: FDA drug label (Bimzelx), UCB, Inc., effective June 16, 2025 (SPL set 26b88358-871f-4c80-9d80-b2fb16477f81), via openFDA; the full label on DailyMed
Is there a generic for bimekizumab (Bimzelx)?
No generic bimekizumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for bimekizumab (Bimzelx)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $8,073.83 per mL (Bimzelx 160 mg/mL autoinjector), up 5% from $7,702.79 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Bimzelx 160 mg/mL autoinjector (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Bimzelx 160 mg/mL autoinjector | Brand | $8,073.83 per mL | n/a | +5% |
| Bimzelx 320 mg/2 mL autoinject | Brand | $8,016.04 per mL | $16,032.07 per autoinj | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the bimekizumab label say about other medicines?
The bimekizumab label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Cyclosporine | drug interactions | … narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate. |
| Methotrexate | drug interactions | Population pharmacokinetic (PK) data analyses indicated that the clearance of BIMZELX was not impacted by concomitant administration of cDMARDs including methotrexate, or by prior exposure to biologics. |
| Warfarin | drug interactions | Therefore, upon initiation or discontinuation of BIMZELX in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification … |
Source: FDA drug label (Bimzelx), UCB, Inc., effective June 16, 2025 (SPL set 26b88358-871f-4c80-9d80-b2fb16477f81), via openFDA; the full label on DailyMed
What do FAERS reports show for bimekizumab?
The FDA Adverse Event Reporting System holds 21,176 reports that list bimekizumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 147 are coded as a death and 1,909 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2025 (10,927, against a median of 3 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as bimekizumab?
7 other medicines are given the same way (subcutaneous) and in the same FDA class as bimekizumab or labeled mainly for the same use (psoriasis), the same class first. Psoriasis lists all 38 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Adalimumab-ryvk | Psoriasis | none listed | $499.12 per unit 40 mg/0.4 mL autoinjector | A presentation being discontinued |
| Risankizumab | Psoriasis | none listed | $22,774.36 per mL 150 mg/mL pen | No current entry |
| Ixekizumab | Psoriasis | none listed | $7,370.72 per mL 80 mg/mL autoinjector | No current entry |
| Secukinumab | Psoriasis | none listed | $3,946.35 per mL 300 mg dose/2 pens (150 mg/pen) | No current entry |
| Spesolimab | Psoriasis | none listed | n/a | No current entry |
| Brodalumab | Psoriasis | none listed | n/a | No current entry |
| Tildrakizumab | Psoriasis | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as bimekizumab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to bimekizumab
- 7 medicines for the same use
- Bimekizumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other